Allergic Contact Dermatitis Research Dashboard
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 23 studies associated with Allergic Contact Dermatitis.
Here is a small sampling of Allergic Contact Dermatitis studies by title:
- Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review
- Cannabinoid Receptor 2 Modulates Maturation of Dendritic Cells and Their Capacity to Induce Hapten-Induced Contact Hypersensitivity
- Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis.
- Selective Cannabinoid Receptor-1 Agonists Regulate Mast Cell Activation in an Oxazolone-Induced Atopic Dermatitis Model.
- Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis
Components of the Allergic Contact Dermatitis Research Dashboard
- Dosing information available for Allergic Contact Dermatitis
- Chemotype guidance for treating Allergic Contact Dermatitis with cannabis
- Synopsis of cannabis research for Allergic Contact Dermatitis
- Individual study details for Allergic Contact Dermatitis
Ready to become a subscriber? Go to our PRICING page.
Select New Condition
Search By Keyword
Overview - Allergic Contact Dermatitis
Description of Allergic Contact Dermatitis
Allergic contact dermatitis is an inflammatory skin disorder that occurs after repeated exposure to an allergen (e.g. nickel, thiomersal, chromium). Orthodox treatments are usually limited to topical or systemic pharmaceuticals (e.g. antihistamines, steroids).Disease Classification
Condition: Allergic Cont. DermatitisDisease Family: Skin Disease
Organ System: Integumentary System
ICD-10 Chapter: Diseases of the Skin and Subcutaneous Tissue
ICD-10 Code: L23
Allergic Contact Dermatitis Symptoms:
Rash, itching, swelling, redness, pain, sometimes blister formationAlso known as:
ACDDrug Interactions
THC Interaction with Pharmaceutical Drugs
- THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example.
- THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), beta-blockers (e.g. propranolol), bronchodilators (e.g. theophylline), or bloodthinners (e.g. warfarin). Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
- Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.
CBD Interaction with Pharmaceutical Drugs
- CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects.
- Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
- Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD
Dosing Considerations
THC Dosage Considerations
- THC micro dose: 0.1 mg to 0.4 mg (0.001mg/kg to 0.005mg/kg)
- THC low dose: 0.5 mg to 5 mg (0.006mg/kg to 0.06mg/kg)
- THC medium dose: 6 mg to 20 mg (0.08mg/kg to 0.27mg/kg)
- THC high dose: 21 mg to 50+ mg (0.28mg/kg to 0.67mg/kg)
(sample conversion calculated on a person weighing 75kg)
CBD Dosage Considerations
- CBD low dose: 0.4 mg to 19 mg (0.005mg/kg to 0.25mg/kg)
- CBD medium dose: 20 mg to 99 mg (0.26mg/kg to 1.32mg/kg)
- CBD high dose: 100 mg to 800+ mg (1.33mg/kg to 10.7mg/kg)
- (upper limits tested ~1,500mg)
(sample conversion calculated on a person weighing 75kg)
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.